摘要
以人a-干扰素(IFN-a)基因为治疗性目的基因,建立了IFN-a基因疗法治疗人黑色素瘤的实验模型并探讨其免疫学机理。方法将人IFN-a基因体外转染成纤维细胞NIH3T3中,获得一株高分泌IFN-a的细胞克隆株NIH3T3-IFN-a+。将该高分泌IFN-a细胞克隆株在体外大量扩增后回植裸鼠腹腔内,测定裸鼠血清中IFN-a的含量并观察对荷瘤裸鼠的治疗效果。结果 12h后裸鼠血清中即能测到IFN-a活性并能维持较长时间,荷瘤裸鼠的存活期明显延长。结论 经成纤维细胞途径能成功地将人IFN-a基因导入体内并有效表达,同时对荷黑色素瘤裸鼠的肿瘤生长有明显的抑制作用,为临床应用IFN-a基因疗法治疗黑色素瘤提供实验依据并建立新的应用方法。
Objective To establish a model of fibroblast cell-mediated human IFN-a gene therapy for anti-melanoma. Methods BMGNeo-IFN-a DNA was transferred into NIH3T3 fibroblasts by the liposome method. The clone secreting the highest level of IFN-a was selected and implanted to mice intraperitoneally. Results From 12 hours after implantation, IFN-a activity could be detected in serum of the animal and was sustained for a long time. We used the model to treat the nude mice inoculated with melanoma and found that the growth of M21 cells was inhibited obviously. Conclusions The results demonstrated that fibroblasts could successfully transfer and express hIFN-a gene in vivo and the fibroblast cell-mediated gene therapy could be used to treat human melanoma.
出处
《中华整形外科杂志》
CSCD
北大核心
2000年第5期298-301,共4页
Chinese Journal of Plastic Surgery
基金
上海市科技发展基金(编号:994119009)